Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Milestone Pharmaceuticals develops innovative cardiovascular medicines, focusing on rapid-onset nasal spray treatments for arrhythmias like PSVT and AFib-RVR. Its flagship product, CARDAMYST (etripamil), aims to provide self-administered, fast-acting therapy for episodic heart rhythm disturbances. The company targets the U.S. and global markets, leveraging proprietary formulations, clinical data, and strategic partnerships to address unmet needs in acute cardiovascular care.
This description was generated via AI from an annual report. Updated about 1 year ago.